Retour sur lavenir.net
   CMB.TECH 11.480 € (+1,59 %)     AB INBEV 62.520 € (-2,07 %)     TINC 11.860 € (-0,34 %)     CENERGY 23.440 € (+6,64 %)     ACKERMANS V.HAAREN 275.000 € (-0,43 %)     KBC ANCORA 77.800 € (-0,26 %)     D'IETEREN GROUP 175.400 € (-0,62 %)     ARGENX SE 646.400 € (-2,88 %)     AGEAS 66.750 € (-1,04 %)     UCB 223.300 € (-1,93 %)     ONWARD MEDICAL 2.680 € (-4,96 %)     TUBIZE-FIN 189.600 € (-3,12 %)     KBC 113.400 € (-0,04 %)     VASTNED 29.450 € (-1,01 %)     SOFINA 216.400 € (-0,73 %)     AZELIS GROUP 11.180 € (-1,15 %)     PROXIMUS 6.480 € (-0,92 %)     MELEXIS 66.750 € (-4,44 %)     WDP 23.140 € (-3,02 %)     XIOR 27.300 € (-1,44 %)     SIPEF 99.300 € (-0,70 %)     TESSENDERLO 21.450 € (0,00 %)     RECTICEL 9.930 € (-0,10 %)     AEDIFICA 71.300 € (-2,06 %)     SYENSQO 56.250 € (+1,81 %)     GBL 78.950 € (-0,88 %)     UMICORE 17.100 € (-0,58 %)     SOLVAY 27.800 € (+1,76 %)     VIOHALCO 14.900 € (+0,68 %)     FAGRON 23.850 € (+0,42 %)     CARE PROPERTY INV. 12.800 € (-0,62 %)     ONTEX GROUP 2.895 € (-1,86 %)     VGP 88.000 € (-0,90 %)     BARCO 9.480 € (-0,21 %)     NYXOAH 2.475 € (-4,26 %)     HYBRID SOFTWARE GR 3.980 € (0,00 %)     ELIA GROUP 137.300 € (-1,22 %)     EVS BROADC.EQUIPM. 37.000 € (+2,64 %)     MONTEA 69.700 € (-1,27 %)     VAN DE VELDE 32.800 € (+0,61 %)     IBA 13.400 € (-1,18 %)     FLUXYS BELGIUM D 21.700 € (+0,93 %)     GIMV 47.900 € (-0,42 %)     DEME GROUP 187.000 € (+0,11 %)     BEKAERT 41.750 € (+0,24 %)     JENSEN-GROUP 70.000 € (-0,28 %)     RETAIL ESTATES 67.400 € (-1,89 %)     ASCENCIO 49.550 € (-0,50 %)     COFINIMMO 83.800 € (-1,47 %)     SHURGARD 25.800 € (-2,46 %)     WERELDHAVE BELGIUM 53.400 € (+1,14 %)     KINEPOLIS GROUP 30.700 € (-0,65 %)     FLORIDIENNE 53.000 € (-0,93 %)     EXMAR 10.600 € (-0,93 %)     ECONOCOM GROUP 1.415 € (-2,41 %)     BPOST 1.792 € (-2,08 %)     IMMOBEL 20.900 € (+0,48 %)     ORANGE BELGIUM 21.000 € (0,00 %)     COLRUYT 32.900 € (-0,72 %)     HOME INVEST BE. 19.320 € (-0,21 %)  
   ATON 0.014 € (-30,10 %)     FDJ UNITED 23.400 € (+0,13 %)     KLEA HOLDING 0.193 € (+0,52 %)     VIRIDIEN 143.500 € (-2,05 %)     EXOSENS 63.050 € (-1,56 %)     SCOR SE 31.020 € (-2,94 %)     BNP PARIBAS ACT.A 90.750 € (-0,84 %)     STMICROELECTRONICS 45.315 € (+7,39 %)     BE SEMICONDUCTOR 241.200 € (+2,51 %)     SANOFI 77.860 € (-1,31 %)     KERING 232.100 € (-1,69 %)     UMG 19.270 € (-0,64 %)     IMERYS 21.320 € (-1,57 %)     PHILIPS KON 21.800 € (-5,83 %)     SPIE 48.680 € (+0,16 %)     VINCI 125.900 € (-2,06 %)     AIRBUS 175.980 € (+5,95 %)     SHELL PLC 37.838 € (-0,31 %)     AIR FRANCE -KLM 8.778 € (-1,70 %)     FNAC DARTY 35.250 € (-0,14 %)     L'OREAL 363.200 € (-0,90 %)     PROSUS 40.665 € (-0,20 %)     JCDECAUX 18.720 € (-0,74 %)     LVMH 446.600 € (-1,79 %)     ARKEMA 62.250 € (+0,40 %)     STIF 44.720 € (-0,36 %)     VEOLIA ENVIRON. 34.750 € (-2,55 %)     STELLANTIS NV 6.663 € (-0,57 %)     TELEPERFORMANCE 55.480 € (+2,55 %)     ABN AMRO BANK N.V. 29.380 € (+0,41 %)     UNILEVER 48.725 € (-1,16 %)     BOUYGUES 49.370 € (-0,82 %)     CREDIT AGRICOLE 17.315 € (+0,03 %)     ARCELORMITTAL SA 49.230 € (-0,18 %)     POSTNL 0.945 € (-5,74 %)     ING GROEP N.V. 23.965 € (-0,21 %)     SCHNEIDER ELECTRIC 272.000 € (+0,44 %)     VOPAK 41.640 € (-1,42 %)     LEGRAND 149.400 € (+1,01 %)     ASM INTERNATIONAL 816.200 € (+0,52 %)     FORVIA 9.816 € (+0,68 %)     HERMES INTL 1 606.000 € (-1,02 %)     ASML HOLDING 1 193.600 € (+1,86 %)     RENAULT 29.860 € (-1,03 %)     SAINT GOBAIN 77.020 € (-0,41 %)     AHOLD DEL 40.010 € (-1,72 %)     TKH GROUP 43.100 € (+0,56 %)     CARREFOUR 16.600 € (-0,27 %)     ADYEN 949.400 € (-0,48 %)     TOTALENERGIES 78.520 € (+0,32 %)     IMCD 97.440 € (-0,18 %)     VETOQUINOL 76.600 € (-4,84 %)     HEINEKEN 64.720 € (-3,11 %)     SAFRAN 269.300 € (-0,74 %)     NN GROUP 73.820 € (+0,05 %)     ASR NEDERLAND 63.960 € (-0,62 %)     CTP 15.560 € (-0,77 %)     GECINA 71.500 € (-0,90 %)     AXA 40.240 € (-1,81 %)     EURONEXT 142.600 € (-1,25 %)  
News Réglementées
29/04/2026 09:05

Coreline Soft Unveils 'G-BA Compliance-Optimized AI Infrastructure' in Step with Germany's Reimbursed Lung Cancer Screening Rollout

EQS-News: Coreline Soft / Key word(s): Product Launch
Coreline Soft Unveils 'G-BA Compliance-Optimized AI Infrastructure' in Step with Germany's Reimbursed Lung Cancer Screening Rollout

29.04.2026 / 09:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


To Demonstrate Integrated Double Reading, QA, and Longitudinal Follow-Up Platform 'AVIEW HUB' at RöKo 2026 in May

SEOUL, South Korea, April 29, 2026 /PRNewswire/ -- Coreline Soft, a global medical artificial intelligence (AI) company, announced the launch of an operational AI infrastructure designed to meet Germany's national reimbursement requirements for lung cancer screening under the statutory health insurance system (GKV).

Coreline Soft

As Germany's lung cancer screening program entered full implementation in April 2026, AI-based analysis became a mandatory requirement at every reading stage. The program is structured around eight dedicated EBM billing codes with extrabudgetary funding, where AI-assisted detection is a mandatory requirement for reimbursement claims and program participation.

From Accuracy to Operational Infrastructure: A New Competitive Standard for Medical AI

Germany's Federal Joint Committee (G-BA) has established core requirements including double reading, quality assurance (QA), and data compliance. AI-supported analysis is required in both first and second reads, while any discrepancy between interpretations must be resolved through a formal consensus process.

As a result, hospitals are increasingly expected to build integrated screening infrastructure capable of managing:

  • Multi-site reading collaboration
  • Discordance management between radiologists
  • GDPR-compliant data handling
  • Standardized reporting systems

Germany's lung cancer screening initiative is not a one-time project, but a recurring national program based on repeat examinations. Therefore, longitudinal follow-up functionality to monitor changes in pulmonary nodules over time is also considered essential. The screening workflow requires an integrated operational framework including dual reading across institutions, structured reporting, longitudinal follow-up, and audit-ready documentation aligned with national reimbursement criteria.

AVIEW HUB: A Policy-Aligned Platform Built for Reimbursement-Ready Operations

Coreline Soft provides standardized AI-assisted detection and analysis through AVIEW LCS Plus, while AVIEW HUB manages multi-site workflows, second reading, and consensus processes across the screening network.

The platform enables:

  • Independent workflow management for first and second readings
  • Automatic alerts and consensus workflows when discrepancies occur
  • GDPR-compliant pseudonymization of patient data
  • Standardized reading environments across multiple institutions

By allowing hospitals with different imaging devices, systems, and workflows to operate under the same AI analysis standards, AVIEW HUB helps minimize interpretation variability while supporting compliance with national quality benchmarks.

The platform also includes longitudinal follow-up functions that automate nodule change analysis and long-term data accumulation—capabilities expected to play a critical role as screening volumes expand nationwide.

As a result, AVIEW HUB functions not merely as a reading support tool, but as infrastructure that enables both screening operations and reimbursement execution.

Live Reimbursement Workflow Demonstration at RöKo 2026

Coreline Soft will present real-world AVIEW HUB operational scenarios based on Germany's reimbursement environment at RöKo 2026, taking place this May.

Drawing on reference sites established at leading German institutions, including Charité and Heidelberg University Hospital, the company will demonstrate how AI can support not only reading efficiency, but also workflow standardization and scalable screening operations.

Ahead of the congress, Coreline Soft will host a global webinar on May 5 at 6:00 PM (Germany time), titled:

"Lungenkrebs-Screening in Deutschland 2026: Vom Start der Erstattung zur interdisziplinären Versorgung."

The session will feature leading experts actively involved in Germany's lung cancer screening implementation:

  • PD. Dr. Jens Vogel-Claussen (Charité Berlin): "LCS @ Charité Berlin" — Exploring the clinical implementation of screening.
  • PD. Dr. med. Kaid Darwiche (Lungenklinik Hemer - University Medicine Bochum): "Modern minimally invasive diagnostic pathways for positive screening results."
  • PD. Dr. med. Marcel Opitz (Röntgeninstitut Düsseldorf): "LCS @ Röntgeninstitut Düsseldorf: Networks and operational potentials."

Moderated by Melisande Rouger, the webinar will explore how Germany's screening program is transitioning from reimbursement rollout to interdisciplinary care delivery, highlighting real-world clinical pathways, collaboration models, and system-level challenges.

Logo - https://mma.prnewswire.com/media/2521520/CorelineSoft_Logo.jpg

Cision View original content:https://www.prnewswire.com/de/pressemitteilungen/coreline-soft-unveils-g-ba-compliance-optimized-ai-infrastructure-in-step-with-germanys-reimbursed-lung-cancer-screening-rollout-302755563.html

rt.gif?NewsItemId=EN45279&Transmission_Id=202604290300PR_NEWS_EURO_ND__EN45279&DateId=20260429


29.04.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2317312  29.04.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière